LT2540728T - Heterociklinis junginys - Google Patents

Heterociklinis junginys

Info

Publication number: LT2540728T
Authority: LT; Lithuania
Prior art keywords: heterocyclic compound; heterocyclic; compound
Prior art date: 2010-02-17

Application number

LTEP11744685.6T

Other languages

English (en)

Inventor

Misaki Homma

Toru Miyazaki

Yuya Oguro

Osamu Kurasawa

Original Assignee

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-17

Filing date

2011-02-16

Publication date

2019-06-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2540728(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-02-16 Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited

2019-06-25 Publication of LT2540728T publication Critical patent/LT2540728T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

LTEP11744685.6T 2010-02-17 2011-02-16 Heterociklinis junginys LT2540728T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2010031899		2010-02-17
JP2010131950		2010-06-09
PCT/JP2011/053303 WO2011102399A1 (ja)	2010-02-17	2011-02-16	複素環化合物

Publications (1)

Publication Number	Publication Date
LT2540728T true LT2540728T (lt)	2019-06-25

Family

ID=44482985

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP11744685.6T LT2540728T (lt)	2010-02-17	2011-02-16	Heterociklinis junginys

Country Status (37)

Country	Link
US (6)	US8722660B2 (lt)
EP (2)	EP2540728B1 (lt)
JP (1)	JP5689454B2 (lt)
KR (1)	KR101735868B1 (lt)
CN (1)	CN102844320B (lt)
AU (1)	AU2011216404B2 (lt)
BR (1)	BR112012020311B1 (lt)
CA (1)	CA2790284C (lt)
CL (1)	CL2012002250A1 (lt)
CO (1)	CO6592104A2 (lt)
CR (1)	CR20120448A (lt)
CY (1)	CY1121792T1 (lt)
DK (1)	DK2540728T3 (lt)
DO (1)	DOP2012000224A (lt)
EA (1)	EA020724B1 (lt)
EC (1)	ECSP12012160A (lt)
ES (1)	ES2733221T3 (lt)
GE (1)	GEP20146202B (lt)
HR (1)	HRP20190947T1 (lt)
HU (1)	HUE043514T2 (lt)
IL (1)	IL221442A0 (lt)
LT (1)	LT2540728T (lt)
MA (1)	MA34064B1 (lt)
ME (1)	ME03410B (lt)
MX (1)	MX353500B (lt)
MY (1)	MY164776A (lt)
NZ (1)	NZ602089A (lt)
PE (1)	PE20130184A1 (lt)
PH (1)	PH12012501650B1 (lt)
PL (1)	PL2540728T3 (lt)
PT (1)	PT2540728T (lt)
RS (1)	RS58796B1 (lt)
SG (1)	SG183304A1 (lt)
SI (1)	SI2540728T1 (lt)
SM (1)	SMT201900385T1 (lt)
TN (1)	TN2012000401A1 (lt)
WO (1)	WO2011102399A1 (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY33554A (es) *	2010-08-11	2012-02-29	Millennium Pharm Inc	Heteroarilos y usos de los mismos
WO2015115355A1 (ja)	2014-01-31	2015-08-06	カルナバイオサイエンス株式会社	抗がん剤組成物
TW201620879A (zh)	2014-04-28	2016-06-16	杜邦股份有限公司	除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) *	2014-05-05	2019-01-08	Signalrx Pharmaceuticals, Inc.	Heterocyclic compound classes for signaling modulation
EP3858996B1 (en)	2015-12-07	2022-08-03	Zymergen Inc.	Microbial strain improvement by a htp genomic engineering platform
US10221191B2 (en)	2015-12-22	2019-03-05	SHY Therapeutics LLC	Compounds for the treatment of cancer and inflammatory disease
DK3436463T3 (da) *	2016-03-28	2021-08-30	Takeda Pharmaceuticals Co	Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat
EA035560B1 (ru) *	2016-07-28	2020-07-07	Такеда Фармасьютикал Компани Лимитед	Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
JP7071383B2 (ja)	2016-11-08	2022-05-18	キャンサー・リサーチ・テクノロジー・リミテッド	ｃｄｃ７阻害剤としてのピリミジノン誘導体
JP2020508675A (ja)	2017-03-01	2020-03-26	武田薬品工業株式会社	Ｃｄｃ７阻害剤の効果を予測する方法
US10745410B2 (en)	2017-05-21	2020-08-18	Zenji Research Laboratories	Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents
SG11201911929XA (en)	2017-06-21	2020-01-30	SHY Therapeutics LLC	Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CA3095264A1 (en) *	2018-04-02	2019-10-10	Takeda Pharmaceutical Company Limited	Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one
TWI846703B (zh)	2018-06-19	2024-07-01	日商武田藥品工業股份有限公司	癌症治療方法
CA3106557A1 (en) *	2018-07-19	2020-01-23	Takeda Pharmaceutical Company Limited	Pharmaceutical compositions with a cdc7 inhibitor
WO2020132071A1 (en)	2018-12-19	2020-06-25	Shy Therapeutics. Llc	Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
SG11202113212YA (en) *	2019-05-30	2021-12-30	Chia Tai Tianqing Pharmaceutical Group Co Ltd	Tetracyclic compounds as cdc7 inhibitors
CA3146792A1 (en)	2019-07-19	2021-01-28	Takeda Pharmaceutical Company Limited	Combination therapy for cancer treatment
JP2022546294A (ja) *	2019-08-20	2022-11-04	チアタイティエンチンファーマシューティカルグループカンパニーリミテッド	Ｃｄｃ７阻害剤として使用される四環式化合物
WO2021113492A1 (en)	2019-12-06	2021-06-10	Schrödinger, Inc.	Cyclic compounds and methods of using same
US20230365584A1 (en) *	2020-09-10	2023-11-16	Schrödinger, Inc.	Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
TW202227457A (zh) *	2020-11-30	2022-07-16	大陸商正大天晴藥業集團股份有限公司	作為Cdc7抑制劑的鹽型及其晶型
CN112661770B (zh) *	2020-12-24	2022-11-08	南京正济医药研究有限公司	一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
EP4288050A1 (en)	2021-02-08	2023-12-13	Takeda Pharmaceutical Company Limited	Combination therapy for cancer treatment
CN117120447A (zh) *	2021-03-18	2023-11-24	薛定谔公司	环状化合物和其使用方法
TW202300150A (zh) *	2021-03-18	2023-01-01	美商薛定諤公司	環狀化合物及其使用方法
EP4416156A1 (en) *	2021-10-13	2024-08-21	Remix Therapeutics Inc.	Compounds and methods for modulating nucleic acid splicing
WO2025160538A1 (en) *	2024-01-26	2025-07-31	The Board Of Regents Of The University Of Texas System	Compositions and methods for treating hair graying and loss associated with aging
WO2025168620A1 (en)	2024-02-07	2025-08-14	Bayer Aktiengesellschaft	Heteroaryl-substituted 4,5-dihydro-1h-2,4,5-oxadiazines as novel fungicides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196207A (en) *	1977-05-23	1980-04-01	Ici Australia Limited	Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DE19644228A1 (de) *	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
AUPO721997A0 (en)	1997-06-06	1997-07-03	Queensland Institute Of Medical Research, The	Anticancer compounds
JP2002105081A (ja)	2000-07-28	2002-04-10	Nikken Chem Co Ltd	新規チオフェンニ環化合物
KR20030034232A (ko)	2000-09-29	2003-05-01	닛뽕소다 가부시키가이샤	티에노피리미딘 화합물 및 그 염 및 제조방법
US6503914B1 (en)	2000-10-23	2003-01-07	Board Of Regents, The University Of Texas System	Thienopyrimidine-based inhibitors of the Src family
EP1383771A1 (en)	2001-04-20	2004-01-28	Vertex Pharmaceuticals Incorporated	9-deazaguanine derivatives as inhibitors of gsk-3
DE60304718T2 (de)	2002-08-06	2007-04-26	Astrazeneca Ab	Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
EP1646615B1 (en)	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
ES2324536T7 (es) *	2003-06-11	2012-03-16	Xention Limited	Derivados de tenopirimidina como inhibidores de los canales de potasio.
US20050032869A1 (en) *	2003-07-08	2005-02-10	Pharmacia Italia S.P.A.	Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7279575B2 (en)	2003-08-08	2007-10-09	Pfizer Italia S.R.L.	Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2005014572A1 (en) *	2003-08-08	2005-02-17	Pharmacia Italia S.P.A.	Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2005095386A1 (en)	2004-03-30	2005-10-13	Chiron Corporation	Substituted thiophene derivatives as anti-cancer agents
EP2520652B1 (en)	2004-04-09	2015-06-10	Genecare Research Institute Co., Ltd	Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
CA2595127A1 (en)	2005-01-19	2006-07-27	Paul J. Coleman	Mitotic kinesin inhibitors
JP2009501217A (ja)	2005-07-15	2009-01-15	アストラゼネカアクチボラグ	治療薬
CA2621181C (en)	2005-08-30	2011-04-19	Asahi Kasei Pharma Corporation	5-isoquinolinesulfonamide compounds
FI20055498A0 (fi)	2005-09-16	2005-09-16	Biotie Therapies Corp	Sulfonamidijohdannaisia
US20070142414A1 (en) *	2005-12-16	2007-06-21	Pharmacia Italia S.P.A.	N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en)	2005-12-19	2009-11-17	Nerviano Medical Sciences S.R.L.	Heteroarylpyrrolopyridinones active as kinase inhibitors
KR100846988B1 (ko)	2006-03-06	2008-07-16	제일약품주식회사	신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
WO2008082839A2 (en)	2006-12-29	2008-07-10	Abbott Laboratories	Pim kinase inhibitors as cancer chemotherapeutics
US20090030196A1 (en) *	2006-12-29	2009-01-29	Abbott Laboratories	Pim kinase inhibitors as cancer chemotherapeutics
CL2008000252A1 (es)	2007-01-29	2008-03-14	Xenon Pharmaceuticals Inc	Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
WO2009001214A2 (en)	2007-06-28	2008-12-31	Pfizer Products Inc.	Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en)	2007-11-02	2009-05-07	Wyeth	Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US20110098288A1 (en)	2008-03-11	2011-04-28	Jeremy Major	Sulfonamides as zap-70 inhibitors
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
JP2011526693A (ja)	2008-06-26	2011-10-13	ディナファーバーキャンサーインスティチュート，インコーポレイテッド	転移に関連する徴候および決定因子、ならびにそれらの使用方法
EP2403857B1 (en)	2009-03-05	2013-12-04	Takeda Pharmaceutical Company Limited	Thienopyrimidine as cdc7 kinase inhibitors
WO2010126002A1 (ja)	2009-04-28	2010-11-04	塩野義製薬株式会社	ヘテロ環スルホンアミド化合物を含有する医薬
US20120238533A1 (en)	2009-09-11	2012-09-20	Bayer Pharma Aktiengesellschaft	(Heteroarylmethyl) Thiohydantoins as anticancer drugs
TW201111378A (en)	2009-09-11	2011-04-01	Bayer Schering Pharma Ag	Substituted (heteroarylmethyl) thiohydantoins
JO2978B1 (en)	2009-12-21	2016-03-15	ايلي ليلي اند كومباني	MGLU2 aids

2011
- 2011-02-16 MX MX2012009602A patent/MX353500B/es active IP Right Grant
- 2011-02-16 SI SI201131722T patent/SI2540728T1/sl unknown
- 2011-02-16 AU AU2011216404A patent/AU2011216404B2/en active Active
- 2011-02-16 HU HUE11744685A patent/HUE043514T2/hu unknown
- 2011-02-16 MA MA35205A patent/MA34064B1/fr unknown
- 2011-02-16 JP JP2012500632A patent/JP5689454B2/ja active Active
- 2011-02-16 LT LTEP11744685.6T patent/LT2540728T/lt unknown
- 2011-02-16 EP EP11744685.6A patent/EP2540728B1/en active Active
- 2011-02-16 MY MYPI2012003715A patent/MY164776A/en unknown
- 2011-02-16 SG SG2012059994A patent/SG183304A1/en unknown
- 2011-02-16 PH PH1/2012/501650A patent/PH12012501650B1/en unknown
- 2011-02-16 PE PE2012001253A patent/PE20130184A1/es active IP Right Grant
- 2011-02-16 CA CA2790284A patent/CA2790284C/en active Active
- 2011-02-16 NZ NZ602089A patent/NZ602089A/en unknown
- 2011-02-16 SM SM20190385T patent/SMT201900385T1/it unknown
- 2011-02-16 EP EP19168244.2A patent/EP3533797B1/en active Active
- 2011-02-16 US US13/578,959 patent/US8722660B2/en active Active
- 2011-02-16 PL PL11744685T patent/PL2540728T3/pl unknown
- 2011-02-16 KR KR1020127024086A patent/KR101735868B1/ko active Active
- 2011-02-16 DK DK11744685.6T patent/DK2540728T3/da active
- 2011-02-16 ME MEP-2019-152A patent/ME03410B/me unknown
- 2011-02-16 HR HRP20190947TT patent/HRP20190947T1/hr unknown
- 2011-02-16 WO PCT/JP2011/053303 patent/WO2011102399A1/ja not_active Ceased
- 2011-02-16 PT PT11744685T patent/PT2540728T/pt unknown
- 2011-02-16 BR BR112012020311-8A patent/BR112012020311B1/pt active IP Right Grant
- 2011-02-16 RS RS20190639A patent/RS58796B1/sr unknown
- 2011-02-16 CN CN201180019478.3A patent/CN102844320B/zh active Active
- 2011-02-16 GE GEAP201112855A patent/GEP20146202B/en unknown
- 2011-02-16 EA EA201290800A patent/EA020724B1/ru unknown
- 2011-02-16 ES ES11744685T patent/ES2733221T3/es active Active
2012
- 2012-08-09 TN TNP2012000401A patent/TN2012000401A1/en unknown
- 2012-08-14 CL CL2012002250A patent/CL2012002250A1/es unknown
- 2012-08-14 IL IL221442A patent/IL221442A0/en active IP Right Grant
- 2012-08-15 DO DO2012000224A patent/DOP2012000224A/es unknown
- 2012-08-29 CR CR20120448A patent/CR20120448A/es unknown
- 2012-09-13 CO CO12158066A patent/CO6592104A2/es active IP Right Grant
- 2012-09-17 EC ECSP12012160 patent/ECSP12012160A/es unknown
2014
- 2014-03-24 US US14/223,259 patent/US8921354B2/en active Active
- 2014-03-24 US US14/223,329 patent/US8933069B2/en active Active
- 2014-12-10 US US14/566,157 patent/US9388195B2/en active Active
2016
- 2016-06-08 US US15/176,893 patent/US9655900B2/en active Active
2017
- 2017-04-11 US US15/484,755 patent/US20170209452A1/en not_active Abandoned
2019
- 2019-07-09 CY CY20191100721T patent/CY1121792T1/el unknown

Also Published As

Publication number	Publication date
JPWO2011102399A1 (ja)	2013-06-17
RS58796B1 (sr)	2019-07-31
US20130029969A1 (en)	2013-01-31
HRP20190947T1 (hr)	2019-07-26
EA020724B1 (ru)	2015-01-30
US8722660B2 (en)	2014-05-13
AU2011216404A1 (en)	2012-09-20
EP2540728A4 (en)	2013-11-06
US20160310494A1 (en)	2016-10-27
US20140228352A1 (en)	2014-08-14
DK2540728T3 (da)	2019-05-13
EP3533797B1 (en)	2023-12-20
NZ602089A (en)	2014-05-30
BR112012020311B1 (pt)	2019-01-29
GEP20146202B (en)	2014-11-25
ECSP12012160A (es)	2013-03-28
US20170209452A1 (en)	2017-07-27
ME03410B (me)	2020-01-20
MY164776A (en)	2018-01-30
KR20130001246A (ko)	2013-01-03
PE20130184A1 (es)	2013-03-09
US8921354B2 (en)	2014-12-30
PH12012501650B1 (en)	2018-11-07
US9388195B2 (en)	2016-07-12
US20140235615A1 (en)	2014-08-21
US20150158882A1 (en)	2015-06-11
SI2540728T1 (sl)	2019-06-28
US9655900B2 (en)	2017-05-23
AU2011216404B2 (en)	2016-04-07
EA201290800A1 (ru)	2013-03-29
CN102844320A (zh)	2012-12-26
IL221442A0 (en)	2012-10-31
TN2012000401A1 (en)	2014-01-30
CA2790284C (en)	2019-01-08
EP2540728B1 (en)	2019-04-10
SMT201900385T1 (it)	2019-09-09
JP5689454B2 (ja)	2015-03-25
MX2012009602A (es)	2012-12-17
MX353500B (es)	2018-01-16
CA2790284A1 (en)	2011-08-25
SG183304A1 (en)	2012-09-27
PH12012501650A1 (en)	2012-10-22
CR20120448A (es)	2012-11-13
PT2540728T (pt)	2019-07-11
EP3533797A1 (en)	2019-09-04
ES2733221T3 (es)	2019-11-28
BR112012020311A2 (pt)	2017-03-01
US8933069B2 (en)	2015-01-13
CL2012002250A1 (es)	2013-02-08
HUE043514T2 (hu)	2019-08-28
EP2540728A1 (en)	2013-01-02
CY1121792T1 (el)	2020-07-31
KR101735868B1 (ko)	2017-05-15
PL2540728T3 (pl)	2019-09-30
MA34064B1 (fr)	2013-03-05
WO2011102399A1 (ja)	2011-08-25
CN102844320B (zh)	2016-03-23
DOP2012000224A (es)	2013-01-31
CO6592104A2 (es)	2013-01-02

Publication	Publication Date	Title
IL221442A0 (en)	2012-10-31	Heterocyclic compound
ZA201300950B (en)	2014-04-30	Heterocyclic compound
IL225770A0 (en)	2013-06-27	Heterocyclic compounds
PL2521450T3 (pl)	2015-07-31	Grzybobójcze związki heterocykliczne
GB201008134D0 (en)	2010-06-30	Compounds
HUE040101T2 (hu)	2019-02-28	Szubsztituált piridinon-piridinil-származékok
GB201007347D0 (en)	2010-06-16	Compounds
EP2709609A4 (en)	2015-08-26	HETEROCYCLIC COMPOUNDS
EP2649050A4 (en)	2014-04-23	LINKS
GB201002563D0 (en)	2010-03-31	Compounds
GB201008209D0 (en)	2010-06-30	Compounds
GB201001688D0 (en)	2010-03-17	Compounds
GB201017315D0 (en)	2010-11-24	Compound
GB201002911D0 (en)	2010-04-07	Compound
GB201007789D0 (en)	2010-06-23	Novel Compound
GB201002216D0 (en)	2010-03-31	Compounds
GB201001796D0 (en)	2010-03-24	Compounds
GB201008210D0 (en)	2010-06-30	Compounds
GB201007209D0 (en)	2010-06-16	Compound
GB201013507D0 (en)	2010-09-22	Compounds
GB201021416D0 (en)	2011-01-26	Novel heterocyclic compounds
GB201009514D0 (en)	2010-07-21	Novel heterocyclic compounds
GB201008820D0 (en)	2010-07-14	Compound
GB201021228D0 (en)	2011-01-26	Compound
GB201015798D0 (en)	2010-10-27	Compound